Recent news on Xifaxan

Salix Pharmaceuticals Previews Digestive Disease Week 2007  -  May 17, 2007
Genetic Engineering News (press release),XIFAXAN(R) (rifaximin) tablets 200 mg are indicated for the treatment of patients (greater than or equal to 12 years of age) with travelers' diarrhea caused

Lindgren family's plight prompts donations  -  May 17, 2007
The Journal News / Lohud.com,Lindgren had largely been getting by with samples, but had run out of the antibiotic, Xifaxan, this week. His wife, Ann Lindgren, said they were going to

Salix Pharmaceuticals Reports 1Q2007 Results  -  May 8, 2007
PharmaLive.com (press release),XIFAXAN(R) revenue for the first quarter of 2007 was $15.4 million, a 134% increase compared to the first quarter of 2006. COLAZAL(R) generated revenue of

Salix Pharmaceuticals Announces 1Q2007 Financial Results ...  -  Apr 24, 2007
PharmaLive.com (press release),Balsalazide disodium tablets, Granulated Mesalamine, SANVAR(R) (600 ug vials vapreotide acetate powder) and Xifaxan are under development for additional

Salix Pharmaceuticals to Present At CIBC World Markets Conference  -  Apr 4, 2007
Business Wire (press release),Balsalazide tablets, Granulated Mesalamine, SANVAR ® (600 ug vials vapreotide acetate powder) and Xifaxan for additional indications are under development.

Salix Pharmaceuticals Licenses DIACOL(TM) to Dr. Falk Pharma in Europe  -  Apr 17, 2007
Genetic Engineering News (press release),Balsalazide disodium tablets, Granulated Mesalamine, SANVAR(R) (600 ug vials vapreotide acetate powder) and Xifaxan are under development for additional

Salix Pharmaceuticals Reports 4Q2006 and FY2006 Results  -  Feb 28, 2007
Business Wire (press release),XIFAXAN ® revenue for the fourth quarter of 2006 was $18.7 million, a 61% increase compared to the fourth quarter of 2005, and XIFAXAN revenue for 2006 was

Salix Pharmaceuticals Acquires PEPCID(R) Oral Suspension  -  Mar 1, 2007
PipelineReview.com (press release),If XIFAXAN® is approved for hepatic encephalopathy and C. difficile-associated diarrhea, these hospital-based indications, together with PEPCID Oral

Salix Pharmaceuticals Acquires Pepcid Oral Suspension  -  Feb 28, 2007
PharmaLive.com (press release),Balsalazide tablets, Granulated Mesalamine, SANVAR(R) (600 ug vials vapreotide acetate powder) and Xifaxan for additional indications are under development.

Zacks Analyst Blog Highlights: Xoma, Novartis, Salix ...  -  Mar 5, 2007
Business Wire (press release),We also believe that Salix offers average risk for the biotech group, but would like to see more proof that its antibiotic Xifaxan will drive shareholder

Salix Pharmaceuticals to Present at Two Investment Conferences ...  -  Feb 22, 2007
PharmaLive.com (press release),Balsalazide tablets, Granulated Mesalamine, SANVAR(R) (600 ug vials vapreotide acetate powder) and Xifaxan for additional indications are under development.

New Cure For Stomach Trouble  -  Feb 8, 2007
abc7news.com,Kate tested positive for bacterial overgrowth, so she'll start taking the antibiotic Xifaxan for a month -- which should eliminate her symptoms.

Doctor finds new way to treat IBS  -  Jan 8, 2007
KING5.com (subscription),...study is needed to verify the results. The drug is FDA approved to treat traveler's diarrhea and is available by prescription under the brand name Xifaxan.

Colazal® Pediatric Indication Approved First 5-ASA Approved for ...  -  Dec 20, 2006
dBusinessNews Triangle (press release),Balsalazide tablets, Granulated Mesalamine, SANVAR® (600 ug vials vapreotide acetate powder) and Xifaxan for additional indications are under development.

Colazal® Pediatric Indication Approved First 5-ASA Approved for ...  -  Dec 20, 2006
dBusinessNews Triangle (press release),Balsalazide tablets, Granulated Mesalamine, SANVAR® (600 ug vials vapreotide acetate powder) and Xifaxan for additional indications are under development.

Salix Pharmaceuticals to Present at Thomas Weisel Partners ...  Aug 30, 2006
Salix markets COLAZAL(R), XIFAXAN(R), VISICOL(R), OSMOPREP(TM), AZASAN(R), ANUSOL-HC(R) and PROCTOCORT(R). In August 2006, the FDA approved MOVIPREP(R) for ... -Genetic Engineering News

Salix to buy rights to drug  Sep 5, 2006
...said. Colezal and Xifaxan, an antibiotic approved for traveler's diarrhea, are mostly sold through pharmacies and mail orders. "We ... -News & Observer

Debiopharm and Salix Pharmaceuticals sign license agreement for ...  Sep 5, 2006
Salix markets Colazal(R) (balsalazide disodium) Capsules 750 mg, Xifaxan(R) (rifaximin) tablets 200 mg, Visicol(R) Tablets (sodium phosphate monobasic ... -Canada NewsWire

Salix Pharmaceuticals and Debiopharm Sign SANVAR(R) License ...  Sep 6, 2006
Salix markets Colazal® (balsalazide disodium) Capsules 750 mg, Xifaxan® (rifaximin) tablets 200 mg, Visicol® Tablets (sodium phosphate monobasic monohydrate ... -PipelineReview.com

Salix Pharmaceuticals to Present at Piper Jaffray Health Care ...  -  Nov 23, 2006
dBusinessNews Charlotte (press release),Balsalazide tablets, Granulated Mesalamine, SANVAR® (600 ug vials vapreotide acetate powder) and Xifaxan for additional indications are under development.

COLAZAL Pediatric Exclusivity Granted  29 Aug 2006
Salix also markets XIFAXAN(R), VISICOL(R), OSMOPREP(TM), AZASAN(R), ANUSOL-HC(R) and PROCTOCORT(R). In August 2006, the FDA approved MOVIPREP(R) for bowel ... -dBusinessNews Triangle

Salix Pharmaceuticals Reports 2Q2006 Results  Aug 8, 2006
XIFAXAN(R) revenue for the second quarter of 2006 was $10.4 million, a 61% increase compared to the second quarter of 2005, and XIFAXAN revenue for the first ... -Business Wire

Salix shares surge on strong 2Q sales  Aug 8, 2006
Boosted by strong sales of Xifaxan and additional revenue from Salix's bowel-cleansing products, second quarter revenue swelled from $35.1 million a year ago ... -Triangle Business Journal

Salix Pharmaceuticals to Present at Bank of America Conference  Aug 8, 2006
Salix markets COLAZAL(R), XIFAXAN(R), VISICOL(R), OSMOPREP(TM), MOVIPREP(R), AZASAN(R), ANUSOL-HC(R) and PROCTOCORT(R). Granulated mesalamine is under ... -Business Wire

MoviPrep(R) Granted FDA Marketing Approval; New Two-Liter Liquid ...  Aug 2, 2006
Salix also markets Colazal(R) (balsalazide disodium) Capsules 750 mg, Xifaxan(R) (rifaximin) tablets 200 mg, Visicol(R) Tablets (sodium phosphate monobasic ... -Genetic Engineering News

MOVIPREP(R) Granted FDA Marketing Approval  Aug 3, 2006
Salix also markets Colazal® (balsalazide disodium) Capsules 750 mg, Xifaxan® (rifaximin) tablets 200 mg, Visicol® Tablets (sodium phosphate monobasic ... -PipelineReview.com

Salix Expands XIFAXAN Intellectual Property  Jul 6, 2006
...and have sold and import licensed products related to the use of rifaximin, which the company markets in the United States under the trade name XIFAXAN, with a ... -ag-IP-news Agency

Salix Expands XIFAXAN(R) Intellectual Property; Secures License ...  Jul 5, 2006
...sell and have sold and import licensed products related to the use of rifaximin, which we market in the United States under the trade name XIFAXAN(R), with a ... -Genetic Engineering News

Salix Pharmaceuticals In Arrangement With Cedars-Sinai Medical ...  Jul 5, 2006
...license to make, have made, use, sell and have sold and import licensed products related to the use of rifaximin, which is sold in the US as Xifaxan, with also ... -Trading Markets

Salix Licenses Wider Use For Use Of Patents Used In Bowel Drug  Jul 6, 2006
Salix markets the drug under the name Xifaxan and is seeking Food and Drug Administration approval for its use as an indicator of irritable bowel syndrome. ... -Local Tech Wire

COLAZAL(R) Pediatric Exclusivity Filing Submitted  Jul 5, 2006
Salix also markets XIFAXAN(R), VISICOL(R) Tablets, OSMOPREP(TM) Tablets, AZASAN(R), Anusol-HC(R) 2.5%, Anusol-HC(R) 25 mg Suppository, Proctocort(R) Cream 1 ... -Business Wire



Salix Pharmaceuticals Reports 1Q2006 Results  May 4, 2006
...interval. XIFAXAN revenue for the first quarter of 2006 was $6.6 million, a 153% increase compared to the first quarter of 2005. ... - Genetic Engineering News

Salix Pharma 1Q Profit Up 9 Percent  May 4, 2006
...to $39 million as research and development costs more than doubled because of enrollment in a clinical trial for the irritable bowel syndrome treatment Xifaxan ... - MSN Money

Salix Q1 EPS Rises On Surged Revenues, Yet Misses Estimates ...  May 4, 2006
...last-year quarter. The $6.6 million revenue generated by XIFAXAN was 153% up, compared to the prior-year quarter. Revenues from ... - Trading Markets

Salix Pharmaceuticals to Present at Two Investment Conferences ...  May 8, 2006
Salix markets COLAZAL(R), XIFAXAN(R), VISICOL(R), OSMOPREP(TM), AZASAN(R), ANUSOL-HC(R) and PROCTOCORT(R). MOVIPREP(R) and granulated mesalamine are under ... - Genetic Engineering News

Salix Announces Completion of OsmoPrep(TM) versus Liquid Bowel ...  Apr 19, 2006
Salix also markets COLAZAL(R) (balsalazide disodium) Capsules 750 mg, XIFAXAN(R) (rifaximin) tablets 200 mg, VISICOL(R) Tablets (sodium phosphate monobasic ... - Genetic Engineering News





Salix Pharmaceuticals to Present at Four Investment Conferences ...  Mar 28, 2006
Salix markets COLAZAL(R), XIFAXAN(R), VISICOL(R), OSMOPREP(TM), AZASAN(R), ANUSOL-HC(R) and PROCTOCORT(R). Granulated mesalamine and NRL944 are under ... - Genetic Engineering News

Salix Pharma's Colon-cleansing OsmoPrep Tablets Granted FDA ...  Mar 17, 2006
...preparations.". In August 2005, mutually agreed with ALTANA Pharma US for the early termination of the co-promotion for XIFAXAN tablets 200mg. ... - Trading Markets

OsmoPrep(TM) Tablets Granted FDA Marketing Approval; New Tablet ...  Mar 17, 2006
OsmoPrep,Colazal(R) and Xifaxan(R), Salix's three primary growth drivers, nowcombine to create the focus of our product portfolio. ... - Finanzen.net

From the travel medicine bag, tools to cure what ails you  Mar 10, 2006
For prevention, he prescribes rifaximin (Xifaxan), a drug that remains in the intestinal tract instead of being absorbed systemically throughout the body and ... - Los Angeles Times

Woes slow Medicare drug plan  Mar 8, 2006
His Part D plan initially covered all but two of those. His doctor spent nearly a month trying to justify one of the prescriptions, Xifaxan, Butts said. ... - Anchorage Daily News



Salix Pharmaceuticals Reports 4Q2005 and FY2005 Results; 2005 ...  Feb 24, 2006
...-- VISICOL(R) and INKP-102 acquired via merger with InKine Pharmaceutical Company, Inc. -- Late-stage clinical trials initiated for XIFAXAN in the treatment of ... - Genetic Engineering News,

Salix shares fall over earnings outlook  Feb 24, 2006
Company, $2.1 million in licensing fees related to a bowel-cleansing agent acquired from Norgine and a $2.7 million inventory write-off regarding Xifaxan. ... - Raleigh Triangle Business Journal,

Salix Pharmaceuticals to Present at Roth Capital Conference  Feb 14, 2006
Salix markets COLAZAL(R), XIFAXAN(R), VISICOL(R), AZASAN(R), ANUSOL-HC(R) and PROCTOCORT(R). Granulated mesalamine, INKP-102 and NRL944 are under development. ... - Genetic Engineering News,

Salix Pharmaceuticals Development Update; XIFAXAN(R) Trials ...  Jan 11, 2006
...(NASDAQ:SLXP) today reported that initial subjects have been enrolled and dosed in three late-stage trials designed to evaluate XIFAXAN(R) for the treatment of ... - Business Wire

XIFAXAN® Trials Initiated in C. difficile-Associated Diarrhea ...  Jan 12, 2006
...reported that initial subjects have been enrolled and dosed in three late-stage trials designed to evaluate XIFAXAN® for the treatment of C. difficile ... - EndoNurse

Salix Pharmaceuticals Announces 4Q2005 and FY2005 Financial ...  Jan 31, 2006
Salix markets COLAZAL(R), XIFAXAN(R), VISICOL(R), AZASAN(R), ANUSOL-HC(R) and PROCTOCORT(R). Granulated mesalamine, INKP-102 and NRL944 are under development. ... - Genetic Engineering News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional